Redeye makes mixed estimate revisions on the back of Nekkar’s H1’24 report that beat our EPS forecas...
Redeye comments on Lipigon's Q2 report 2024. The most significant event since our last update was th...
Genom marknadsföringssatsningar, registrerat JV i Kina, ett breddat distributionsnätverk samt godkän...
Prostatype Genomics har nyligen lanserat sitt test Prostatype® på den viktiga amerikanska marknaden ...
Market headwinds continued in Q2 We lower 2025e EBIT on slower recovery in activity Easy comps in '2...
TCECUR Sweden AB (”TCECUR” eller ”Koncernen”) har publicerat Koncernens delårsrapport för det andra ...
XP Chemistries EU-ansökan till EFSA (European Food Safety Authority) har i slutet av juni passerat f...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
The independent Data Monitoring Committee (DMC) recommends to proceed the clinical Tumorad-01, with ...
Nettoomsättningen sjönk med 11% på årsbasis drivet av längre säljcykler och en övergång till en part...
PMD Device Solutions (“PMD”) has consolidated the US acquisition and a combination of cost control a...
At the end of September Beyond Frames internal studio will release “Escaping Wonderland” based on “A...
Redeye concludes that Q2 revenues were weaker than expected, derived from short-term delays and orde...
Luxbright AB (”Luxbright” eller ”Bolaget”) har presenterat en H1-rapport som illustrerar att det kom...
Redeye updates its view of Curasight following the Q2 report and recent events in the company, inclu...
Devport levererade en omsättning och resultat för det andra kvartalet i nivå med marknadens förväntn...
Q2: sales SEK 43m +30% y-o-y, adj. EBIT margin 28% (23%) Raise both '24e-'26e sales and EBIT by 7-5%...
Redeye updates its view on Acarix following its Q2 2024 report.
While the commercialization of Crunchfish’s solution for offline payments has shown a longer sales c...
Redeye updates its estimates and valuation after Navigo’s Q2 2024 report.
